Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Tumour mutational burden: clinical utility, challenges and emerging improvements
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous
mutations present within the cancer genome, varies across and within cancer types. A first …
mutations present within the cancer genome, varies across and within cancer types. A first …
Biomarker-driven personalization of neoadjuvant immunotherapy in melanoma
LL Hoeijmakers, ILM Reijers, CU Blank - Cancer Discovery, 2023 - AACR
The introduction of immunotherapy has ushered in a new era of anticancer therapy for many
cancer types including melanoma. Given the increasing development of novel compounds …
cancer types including melanoma. Given the increasing development of novel compounds …
The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient
H Zhang, Y Ren, F Wang, X Tu, Z Tong, L Liu… - Cancer Gene …, 2024 - nature.com
Colorectal cancer (CRC) is known to be resistant to immunotherapy. In our phase-I clinical
trial, one patient achieved a 313-day prolonged response during the combined treatment of …
trial, one patient achieved a 313-day prolonged response during the combined treatment of …
Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network
The determination of transcriptome profiles that mediate immune therapy in cancer remains
a major clinical and biological challenge. Despite responses induced by immune-check …
a major clinical and biological challenge. Despite responses induced by immune-check …
Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer
Immune checkpoint blockade (ICB) is a promising therapy for solid tumors, but its
effectiveness depends on biomarkers that are not precise. Here, we utilized genome-wide …
effectiveness depends on biomarkers that are not precise. Here, we utilized genome-wide …
Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
E Romanovsky, K Kluck, I Ourailidis, M Menzel… - Cell Death …, 2023 - nature.com
TP53 is the most frequently mutated gene in human cancer. While no TP53-targeting drugs
have been approved in the USA or Europe so far, preclinical and clinical studies are …
have been approved in the USA or Europe so far, preclinical and clinical studies are …
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
LM Boll, J Perera-Bel, A Rodriguez-Vida, O Arpí… - Scientific Reports, 2023 - nature.com
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in
complete remissions even at advanced stages of the disease. However, only a small fraction …
complete remissions even at advanced stages of the disease. However, only a small fraction …
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Purpose To evaluate a new class of blood-based biomarkers, anti-frameshift peptide
antibodies, for predicting both tumor responses and adverse immune events to immune …
antibodies, for predicting both tumor responses and adverse immune events to immune …
Genomic and transcriptomic predictors of response to immune checkpoint inhibitors in melanoma patients: a machine learning approach
Simple Summary Our work provides novel transcriptomic biomarkers that can accurately
predict immune checkpoint inhibitors (ICIs) response in melanoma patients. Using a …
predict immune checkpoint inhibitors (ICIs) response in melanoma patients. Using a …